Advertisement

Management of Thrombotic Microangiopathies in Pregnancy

  • Jeffrey L. Winters
  • Vesna D. Garovic
  • Layana Alrahmani
  • Kristina A. Davis
Chapter

Abstract

Thrombotic microangiopathy (TMA) may occur with pregnancy in the setting of several conditions including severe preeclampsia with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, TTP (thrombotic thrombocytopenic purpura), and HUS (hemolytic uremic syndrome), predominantly in the form of atypical HUS (aHUS). Formation of microthrombi in the microcirculation is a pathological finding common to these disorders, resulting in overlapping clinical presentations. However, certain clinical and laboratory features may facilitate differential diagnosis among these conditions, and provision of appropriate therapy may be dependent upon establishing the underlying cause of TMA.

Keywords

Thombotic thrombocytopenic purpura Hemolytic uremic syndrome HELLP syndrome Therapeutic plasma exchange Thrombotic microangiopathy 

References

  1. 1.
    Neame PB, Hirsh J, Browman G, Denburg J, D’Souza TJ, Gallus A, et al. Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J [Internet]. 1976;114(12):1108–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1084215 [cited 2017 Apr 1]Google Scholar
  2. 2.
    Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med [Internet]. 1991;325(6):393–7. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199108083250604. [cited 2017 Apr 1]CrossRefGoogle Scholar
  3. 3.
    Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood [Internet]. 1997;89(9):3097–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9129011. [cited 2017 Apr 1].Google Scholar
  4. 4.
    Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood [Internet]. 2012;119(24):5888–97. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-02-408914. [cited 2017 Apr 1]CrossRefGoogle Scholar
  5. 5.
    Zhou X, Ye X, Ren Y, Mei C, Ma L, Huang J, et al. Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases. Front Med [Internet]. 2016;10(4):430–6. Available from: http://link.springer.com/10.1007/s11684-016-0492-5. [cited 2017 Apr 1]CrossRefGoogle Scholar
  6. 6.
    Terrell DR, Vesely SK, Hovinga JAK, Lämmle B, George JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol [Internet]. 2010;85(11):844–7. Available from: http://doi.wiley.com/10.1002/ajh.21833. [cited 2017 Apr 1]CrossRefGoogle Scholar
  7. 7.
    George JN, Nester CM, McIntosh JJ. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology [Internet]. 2015;2015(1):644–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26637783. [cited 2017 Apr 1]CrossRefGoogle Scholar
  8. 8.
    Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood [Internet]. 2001;98(9):2730–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11675345. [cited 2017 Apr 1]CrossRefGoogle Scholar
  9. 9.
    Terrell DR, Motto DG, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion [Internet]. 2011;51(10):2237–43. Available from: http://doi.wiley.com/10.1111/j.1537-2995.2011.03125.x. [cited 2017 Apr 1]CrossRefGoogle Scholar
  10. 10.
    Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher [Internet]. 2016;31(3):149–338. Available from: http://doi.wiley.com/10.1002/jca.21470. [cited 2017 Apr 1]Google Scholar
  11. 11.
    Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol [Internet]. 2005;129(1):79–86. Available from: http://doi.wiley.com/10.1111/j.1365-2141.2005.05418.x. [cited 2017 Jun 4]CrossRefGoogle Scholar
  12. 12.
    Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher [Internet]. 2001;16(1):19–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11309826. [cited 2017 Jun 4]CrossRefGoogle Scholar
  13. 13.
    Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol [Internet]. 1996;94(2):383–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8759902. [cited 2017 Jun 4]CrossRefGoogle Scholar
  14. 14.
    Raife TJ, Friedman KD, Dwyre DM. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Transfusion [Internet]. 2006;46(1):74–9. Available from: http://doi.wiley.com/10.1111/j.1537-2995.2005.00674.x. [cited 2017 Jun 4]CrossRefGoogle Scholar
  15. 15.
    Benhamou Y, Baudel J-L, Wynckel A, Galicier L, Azoulay E, Provôt F, et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Am J Hematol [Internet]. 2015;90(6):E127–9. Available from: http://doi.wiley.com/10.1002/ajh.23997. [cited 2017 Apr 1]CrossRefGoogle Scholar
  16. 16.
    Shatzel JJ, Taylor JA. Syndromes of thrombotic microangiopathy. Med Clin North Am. 2017;101(2):395–415.CrossRefPubMedGoogle Scholar
  17. 17.
    Haeger M, Unander M, Norder-Hansson B, Tylman M, Bengtsson A. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol [Internet]. 1992;79(1):19–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1727579. [cited 2017 Apr 1]Google Scholar
  18. 18.
    Derzsy Z, Prohászka Z, Rigó J Jr, Füst G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol [Internet]. 2010;47(7–8):1500–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20181396. [cited 2017 Apr 1]CrossRefGoogle Scholar
  19. 19.
    Abraham KA, Kennelly M, Dorman AM, Walshe JJ. Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol [Internet]. 2003;108(1):99–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12694980. [cited 2017 Apr 1]CrossRefGoogle Scholar
  20. 20.
    De Carolis S, Fatigante G, Ferrazzani S, Trivellini C, De Santis L, Mancuso S, et al. Uterine myomectomy in pregnant women. Fetal Diagn Ther [Internet]. 2001;16(2):116–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11173960. [cited 2017 Apr 1]CrossRefGoogle Scholar
  21. 21.
    American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol [Internet]. 2013;122(5):1122–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24150027. [cited 2017 Apr 1]CrossRefGoogle Scholar
  22. 22.
    Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Woudstra DM, editor. Cochrane database Syst Rev [Internet]. 2010 [cited 2017 Apr 1];(9):CD008148. Available from: http://doi.wiley.com/10.1002/14651858.CD008148.pub2.
  23. 23.
    Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N Engl J Med [Internet]. 2009;361(17):1676–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19846853. [cited 2017 Apr 1]CrossRefGoogle Scholar
  24. 24.
    Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol [Internet]. 2010;21(5):859–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20203157. [cited 2017 Apr 1]CrossRefGoogle Scholar
  25. 25.
    Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol [Internet]. 2016;31(1):15–39. Available from: http://link.springer.com/10.1007/s00467-015-3076-8. [cited 2017 Apr 1]CrossRefGoogle Scholar
  26. 26.
    Roumenina LT, Loirat C, Dragon-Durey M-A, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods [Internet]. 2011;365(1–2):8–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21215749. [cited 2017 Apr 1]CrossRefGoogle Scholar
  27. 27.
    Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, et al. Thrombotic microangiopathy care pathway: a consensus statement for the mayo clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc [Internet]. 2016;91(9):1189–211. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0025619616302580. [cited 2017 Apr 1].CrossRefGoogle Scholar
  28. 28.
    Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Neonatal Med [Internet]. 2005;17(4):239–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16147832. [cited 2017 Apr 1]CrossRefGoogle Scholar
  29. 29.
    Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol [Internet]. 2010;149(3):446–50. Available from: http://doi.wiley.com/10.1111/j.1365-2141.2010.08099.x. [cited 2017 Apr 1]CrossRefGoogle Scholar
  30. 30.
    Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology [Internet]. 2015;220(4):452–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0171298514002289. [cited 2017 Apr 1]CrossRefGoogle Scholar
  31. 31.
    Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol [Internet]. 2016;103(6):703–12. Available from: http://link.springer.com/10.1007/s12185-016-1946-x. [cited 2017 Apr 1].CrossRefGoogle Scholar
  32. 32.
    Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol [Internet]. 2013;122(2 Pt 2):487–9. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006250-201308002-00021. [cited 2017 Apr 1]CrossRefGoogle Scholar
  33. 33.
    Cañigral C, Moscardó F, Castro C, Pajares A, Lancharro A, Solves P, et al. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol [Internet]. 2014;93(8):1421–2. Available from: http://link.springer.com/10.1007/s00277-013-1970-3. [cited 2017 Apr 1]Google Scholar
  34. 34.
    Servais A, Devillard N, Frémeaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant [Internet]. 2016;31(12):2122–30. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfw314. [cited 2017 Apr 1]CrossRefGoogle Scholar
  35. 35.
    Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med [Internet]. 2013;24(6):496–502. Available from: http://www.sciencedirect.com/science/article/pii/S0953620513001374. [cited 2017 Apr 1]CrossRefGoogle Scholar
  36. 36.
    Fakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci [Internet]. 2016;54(2):199–202. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1473050216300118. [cited 2017 Apr 1]CrossRefGoogle Scholar
  37. 37.
    Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood [Internet]. 2008;112(12):4542–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18658028. [cited 2017 Apr 1]CrossRefGoogle Scholar
  38. 38.
    Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE Cohort. Fisk N, editor. PLoS Med [Internet]. 2011 [cited 2017 Apr 1];8(3):e1001013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21445332.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta [Internet]. 2013;34(2):201–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23228435. [cited 2017 Apr 1]CrossRefGoogle Scholar
  40. 40.
    Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood [Internet]. 2014;124(2):211–9. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2014-02-553131. [cited 2017 Apr 1]CrossRefGoogle Scholar
  41. 41.
    Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: a case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apher [Internet]. 2017;32(3):191–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27142429. [cited 2017 Apr 1]CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jeffrey L. Winters
    • 1
  • Vesna D. Garovic
    • 2
  • Layana Alrahmani
    • 3
  • Kristina A. Davis
    • 1
  1. 1.Division of Transfusion Medicine, Department of Pathology and Laboratory MedicineMayo ClinicRochesterUSA
  2. 2.Division of Maternal Fetal Medicine, Department of Obstetrics and GynecologyMayo ClinicRochesterUSA
  3. 3.Division of Nephrology and Hypertension, Department of MedicineMayo ClinicRochesterUSA

Personalised recommendations